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Abstract 
 
Multiple sclerosis is characterized by a wide spectrum of clinical manifestations, among which 
dysfunction of the autonomic nervous system represents an important cause of multiple 
sclerosis related disability. The aim of this review is to give an overview of autonomic 
dysfunction in people with multiple sclerosis, to discuss the interactions between immune and 
autonomic nervous systems and consequences of these interactions on various aspects of 
multiple sclerosis. 
Autonomic dysfunction in people with multiple sclerosis can be demonstrated clinically and 
on molecular level. Clinically it can be demonstrated by measuring autonomic symptoms with 
Composite Autonomic Symptom Score (COMPASS-31) and neurophysiologically, with 
different autonomic nervous system tests. Both symptomatic and objectively determined 
autonomic dysfunction can be related to increased risk of multiple sclerosis disease activity. 
Further supporting these clinical observations are molecular changes on immune cells. 
Changes in the sympathetic autonomic system, like different expression of dopaminergic and 
adrenergic receptor on immune cells, or modulation of the cholinergic anti-inflammatory 
pathway over different subunits of the nicotinic acetylcholine receptor in peripheral immune 
system, may mediate different effects on multiple sclerosis disease activity. 
 
Key words: Multiple sclerosis, autonomic nervous system, cardiovascular autonomic reflexes, 
sudomotor function 
  
Introduction 
 
Inflammation and neurodegeneration are common underlying processes in multiple sclerosis 
(MS), triggered by a pathological activation of the immune system. (1) MS is characterized by 
a wide spectrum of clinical manifestations, among which dysfunction of the autonomic 
nervous system (ANS) represents an important cause of MS related disability. The reason for 
this is a variety of clinical manifestations which are consequences of end organ dysfunction 
that ANS innervates. (2) Recently it has been suggested that pathological interactions between 
the immune and the autonomic systems may fail to trigger anti-inflammatory mechanisms, 
which are essential to prevent repeated inflammatory attacks, a key pathogenic feature of 
MS. (3) Based on limited available data, it can be speculated that both sympathetic and 
parasympathetic ANS function and/or dysfunction have the influence on inflammatory-anti-
inflammatory and neurodegenerative pathways in MS.  
The aim of this review is to give an overview of ANS dysfunction in people with MS (pwMS), 
to discuss the interactions between immune and ANS systems and consequences of these 
interactions on various aspects of MS. 
 
Autonomic nervous system abnormalities in multiple sclerosis 
 
In general, ANS research can be divided into research regarding patient reported symptoms 
(usually using different questionnaires) and assessment of the ANS function/dysfunction in 
the laboratory. One of the most used questionnaire for the investigation of ANS symptoms is 
the Autonomic Symptom Profile which comprises of 169 questions and assesses 11 domains 
of autonomic function. (4) Due to several problems with this instrument, a shortened version, 
the Composite Autonomic Symptom Score (COMPASS-31) questionnaire was developed (31 
questions in 6 autonomic domains: orthostatic intolerance, vasomotor, secretomotor, 
gastrointestinal, bladder, pupillomotor), which provides an autonomic symptom score from 0 
to 100. (5) As COMPASS-31 was found to be suitable for widespread use in autonomic research 
and clinical practice, it has been validated in several languages and we have recently validated 
the Croatian version of COMPASS-31 for use in pwMS. (6) We have found significant 
correlation between expanded disability status scale (EDSS) and the COMPASS-31 total score, 
as well as significant differences between MS phenotypes (clinically isolated syndrome (CIS), 
relapsing remitting MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS 
(PPMS)) in the COMPASS-31 total score, with the lowest score for people with CIS (pwCIS) and 
highest for people with PPMS (pwPPMS). Another Portuguese study showed alterations in at 
least one autonomic symptom domain of the COMPASS-31 in 97.1% participants, with 
gastrointestinal and pupillomotor domains being the most frequently affected. (7) Finally, a 
study by Cortez and colleagues performed on a small group of people with relapsing remitting 
MS (pwRRMS) found no significant relationship between COMPASS-31 and EDSS or disease 
duration, but found significant correlations with the quality of life. (8) The validity of the 
COMPASS-31 is further supported with a recent study showing that people with laboratory 
confirmed ANS dysfunction score higher on certain domains of the scale. (9) Taken into 
account all these studies, we can conclude that COMPASS-31 is an important tool to detect 
ANS symptoms in pwMS and that it can detect ANS symptoms in different MS phenotypes, 
including earliest stages of MS, as well as patients with low level of disability. 
Assessment of the ANS function in the laboratory is another aspect of ANS research, and in 
recent years there has been an upsurge in laboratory ANS investigations in pwMS (Table 1). In 
general, the most extensively investigated part of the ANS is the cardiovascular autonomic 
system due to its availability for testing. Studies that had been using cardiovascular autonomic 
testing have shown that laboratory confirmed parasympathetic nervous system dysfunction 
exists in 0-55% and sympathetic nervous system dysfunction in 0-61% of pwMS (Table 1). The 
main problem with the laboratory examination of ANS function is that different tests are used 
in different laboratories, making comparison between studies very difficult. A nice example of 
the latter is a study by Acevedo et al. showing parasympathetic nervous system dysfunction 
in 43% of pwMS when using heart rate response to Valsalva maneuver and 30% when using 
respiratory sinus arrhythmia. (10) Another factor that can explain observed differences in 
frequency of autonomic dysfunction (AD) is patient population with different characteristics 
(age, disease duration, level of disability, MS phenotype) enrolled in different studies. An 
example of result variability by MS phenotype is study by de Seze et al., that showed 
sympathetic nervous system dysfunction in 0% of pwRRMS, 20% pwSPMS and 32% pwPPMS. 
(11) The only way to overcome these problems is to use standardized battery of ANS tests 
corrected for age and sex in a strictly defined population of pwMS. The initial attempts to 
overcome this problem in pwMS used a method which scored each autonomic test with 0 
points if the result of the test was normal, 1 point if the result was borderline, and 2 points for 
abnormal results. (12) However, this method again could use many different tests and thus 
make the comparison between studies difficult. Another approach is the development of the 
Composite Autonomic Scoring Scale (CASS). CASS is a 10-point scoring scale that uses 
standardized battery of ANS tests including heart rate response to deep breathing and 
Valsalva maneuver as measures of parasympathetic nervous system function, blood pressure 
response to Valsalva maneuver and tilt-table test as measures of sympathetic nervous system 
function and the quantitative sudomotor axon reflex test (QSART) as measures of sudomotor 
function. (13) The maximum CASS is 10, with 4 points for adrenergic and 3 points each for 
sudomotor and cardiovagal failure. Although CASS was initially developed on patients with 
multiple system atrophy, Parkinson’s disease and autonomic neuropathy, it has been 
successfully used in pwMS as well. We have used CASS in a large, well defined cohort of people 
with clinically isolated syndrome (pwCIS) and found that it can detect autonomic dysfunction 
in a large proportion of patients, namely parasympathetic dysfunction in 5 %, sympathetic in 
42.6 % and sudomotor in 32.7 % of participants. (14) In a subsequent study we used CASS in a 
cohort of pwRRMS and progressive MS (PMS), and found that type of multiple sclerosis (RRMS 
or PMS) corrected for age, sex and disease duration, was a statistically significant predictor of 
CASS value. (15) Furthermore, both disease duration and EDSS positively correlated with total 
CASS. These studies indicate that CASS is a valuable tool for evaluation of ANS dysfunction in 
pwMS and using this test enables comparison of the results across different studies.  
Interestingly, in structural disorders of the ANS, like MS, there is a great discrepancy between 
patient reported symptoms of the ANS and laboratory ANS findings. Studies have shown that 
even patients with severe sympathetic dysfunction (orthostatic hypotension with a decrease 
in systolic blood pressure more than 60 mm Hg from baseline during a head-up tilt table test) 
in up to one third of cases can be completely asymptomatic during the head-up tilt table test. 
(16) Similarly, one study has shown no significant association between the presence of 
symptoms of AD and laboratory confirmed autonomic damage. (17)  
The third aspect of the CASS is sudomotor testing. Traditional neurophysiologic 
measurements of sudomotor function include thermoregulatory sweat testing, QSART, 
silicone impressions and sympathetic skin response (SSR). (18) Sweating dysfunction is 
common in MS, particularly in advanced course of disease. The most frequently used test for 
evaluation of sudomotor function in pwMS is SSR, and it has shown sudomotor abnormalities 
in 18-94% pwMS (Table 1). However, this methodology is only a surrogate measure of 
sudomotor function, it shows a high variability within and between subjects and may not be 
evident in many subjects older than 50 years. (18) On the other hand, QSART is used to 
evaluate postganglionic sympathetic cholinergic sudomotor function by measuring the axon-
reflex mediated sweat response and because of this it has rarely been studied in pwMS. 
However, with increased duration of the preganglionic lesion the response on QSART may 
become abnormal as well. This has been shown in a study investigating cholinergic sweating 
responses with pilocarpine iontophoresis in pwMS, which showed diminished peripheral 
sweating responses as a consequence of impairments in central autonomic control of 
sudomotor function. (19) This indicates that QSART may be used for detection of sudomotor 
dysfunction in MS as well. In line with this, we have shown QSART abnormalities in 33% of 
pwCIS, 35.0% of pwRRMS and 73.3% of pwPMS. (14,15) Sudomotor index correlated with both 
disease duration and EDSS in all patients and pwPMS had significantly worse QSART results on 
all tested areas compared to pwRRMS. (15) Whether QSART abnormalities can be used as 
markers of disease progression remains to be elucidated. 
In figure 1, four main questions which arise from these studies are depicted: 1) Can AD be 
related to demyelinating lesions on the MRI?, 2) What happens with AD with the progression 
of MS?, 3) How is AD related to MS disease course? and 4) Is AD related to MS comorbidities? 
 
Can AD be related to demyelinating lesions on the MRI? 
 
As the MRI is most widely used test in the diagnosis and follow-up of pwMS, several studies 
tried to correlate AD with the presence of demyelinating lesions in different brain and/or 
spinal cord regions. Only few studies have found a correlation between ANS dysfunction and 
brainstem lesions on the MRI, two of which found correlation between sympathetic 
cardiovascular dysfunction and brainstem lesions. (14,17,20) On the other hand, one study 
has shown that ANS dysfunction correlates with a spinal cord atrophy, suggesting that 
autonomic dysfunction is secondary to axonal loss, rather than to demyelination. (11) 
Although these results are not robust, as both, brainstem and spinal cord are areas of the 
central nervous system responsible for autonomic dysfunction, they are not surprising. 
Studies on larger well defined cohorts of pwMS using newer MRI techniques might give more 
evidence supporting this association.   
 
What happens with AD with the progression of MS? 
 
Only three studies so far investigated longitudinal evolution of cardiovascular autonomic 
dysfunction in pwMS. (21,22,23) The first study addressing this question enrolled people with 
advanced RRMS and secondary progressive MS (SPMS) with a disease duration from 2-32 
years. Authors only looked at parasympathetic cardiovascular autonomic function over a one-
year period and found progression in two tests measuring parasympathetic function 
(maximum change in heart rate after standing up and the Max/Min ratio after standing up). 
(21) In a study that used similar tests but included people with active RRMS with a disease 
duration ranging from 2-13 years and had a follow-up of two years, authors found a 
progression of the parasympathetic autonomic dysfunction. (22) In the third and final study 
that longitudinally investigated cardiovascular autonomic function in pwMS, authors enrolled 
people with active and stable MS with an average disease duration of 5.5 and 9.3 years, 
respectively, and used tests of parasympathetic and adrenergic sympathetic function. (23) 
During two-year follow-up, only test results of the parasympathetic function worsened, while 
there was no change in results of the adrenergic sympathetic function tests. While there is a 
clear lack of studies with longitudinal evaluation of adrenergic sympathetic function, some 
hypotheses can be generated from cross-sectional studies which evaluated both, adrenergic 
sympathetic and parasympathetic branches, in different MS phenotypes (CIS, RRMS and 
SPMS) which are clearly related to time. It has been shown that in pwCIS parasympathetic 
dysfunction is present in 5% and sympathetic in 43% (14), in pwRRMS parasympathetic 
dysfunction is present in 2% and sympathetic in 36%, while in pwPMS parasympathetic 
dysfunction is present in 20% and sympathetic in 61% (15). If we put these studies into a 
context of longitudinal studies, there seems to exist a distinct pattern of dysautonomia which 
depends on different phases of the disease. 
 
How is AD related to MS disease course? 
 
There are several line of evidence that interactions between the immune and the autonomic 
systems may alter the disease course of MS. (3) However, data on how these abnormalities 
influence evolution of MS over time are sparse. Only two studies investigated the role of ANS 
abnormalities in pwCIS. In a first study, authors investigate whether ANS dysfunction 
presenting as postural orthostatic tachycardia syndrome (POTS) can predict conversion to MS 
in pwCIS over 6-months follow-up. POTS was identified as a significant predictor of early 
conversion to MS with an odds ratio of 2.34. (24) The second study aimed to evaluate the 
potential role of ANS abnormalities on disease activity (relapses and new MRI lesions) and 
disease progression in 121 pwCIS over a mean duration of follow-up of 2.9 years. (25) The 
results have shown that symptoms of AD measured with COMPASS-31 (COMPASS-31 > 7.32) 
increase the risk of next relapse by 2.7 folds in pwCIS. These results are of particular interest 
because a recent study has observed pwMS had significantly higher risk of presenting up to 
10 years prior to a first demyelinating event with gastric, intestinal, urinary and anorectal 
disturbances, anxiety, depression, insomnia, fatigue, headache and various types of pain. (26) 
These autonomic symptoms that precede MS for up to 10 years are called MS prodrome and 
the more symptoms are present so is the risk of MS greater. If we put the results of the former 
study into the context with the autonomic MS prodrome, we may speculate that ANS is an 
important predictor of disease activity, even before the first demyelinating event. If these 
results would be confirmed in a second independent study, they would be of great importance 
for early detection of pwMS at risk for higher disease activity. 
 
Is AD related to MS comorbidities? 
 
As discussed previously, one of the most frequent ANS abnormalities in MS are abnormalities 
of the cardiovascular autonomic system. These abnormalities might be related to 
epidemiological studies showing that pwMS may have an increased risk of ischemic heart 
disease and congestive heart failure when compared with the general population (26), and 
that pwMS have a markedly increased risk of myocardial infarction in the first year after the 
MS diagnosis. (28) A recently published retrospective study found that pwMS have adrenergic 
hyperactivity expressed as an increase in α adrenergic baroreflex sensitivity (α-BRSa) 
compared with healthy controls (HC). (29) In the same study authors have also observed a 
positive correlation between α-BRSa and systolic BP in the tilted position. These results are 
interesting knowing that that adrenergic hyperactivity, which is a hallmark of arterial 
hypertension, (30) may contribute to the increased risk of ischemic heart disease and 
congestive heart failure in pwMS. Further studies are needed in order to confirm these 
preliminary results. 
 ANS-immune system interactions and their role in MS 
 
Interactions between ANS and immune system exist on several levels and are out of scope of 
this review article. Several recent articles review experimental evidence that the ANS has a 
crucial role in the communication between the nervous system and the immune system. 
(53,54)  
Few studies investigated changes in the interaction between ANS and immune system in 
pwMS. In vitro studies have shown that interferon beta leads to reduction of intracellular and 
increased extracellular levels of epinephrine, norepinephrine and dopamine. (55) This effect 
is the result of induction of catecholamine release from the cells to the medium and increased 
production of all three catecholamines. These results are interesting if we put them into a 
clinical context, with a study that showed reduction of the likelihood for a relapse with 
increasing levels of serum epinephrine. (25) 
In both RRMS and PPMS, there is an increase in the beta2 adrenergic receptor density on 
mononuclear cells in peripheral blood which is associated with clinical and radiological disease 
activity. (56,57) Furthermore, responsiveness of beta2 adrenergic receptors to isoproterenol 
was shown to be absent in untreated patients and restored after interferon beta treatment. 
(58) On the other hand, gene expression studies showed that the expression of mRNA for beta 
adrenergic receptors is reduced in mononuclear cells of peripheral blood from untreated 
patients with relapsing MS. (59) In untreated pwMS there is a reduction of expression and 
activity of D1-like dopaminergic receptors and β2-adrenergic receptors on circulating 
peripheral blood mononuclear cells and on CD4+ T effector lymphocytes and overexpression 
of D1-like dopaminergic receptors on CD4 + CD25high T regulatory lymphocytes. (60) The 
opposite is seen in pwMS treated with interferon beta. (59,60) Furthermore, dopaminergic 
receptor D3 and α2A-adrenergic receptor mRNAs in peripheral blood mononuclear cells, and 
dopaminergic receptor D5 mRNA in T regulatory cells may be associated with the risk of 
conversion to MS in pwCIS within 12 months of clinical presentation. (61) 
A second branch of the ANS, the parasympathetic nervous system has a major role in alerting 
the central nervous system about the presence of inflammation via inflammatory cytokines. 
(62) These afferent signals are transmitted by the vagal nerve and trigger an anti-inflammatory 
response, termed “cholinergic anti-inflammatory pathway”, which is postulated to suppress 
inflammatory and immune responses by integrating signaling in the immune and nervous 
systems. (3,63) This efferent part of the cholinergic anti-inflammatory pathway ends in the 
alpha 7 subunit of nicotinic acetylcholine receptors, which are expressed in immune cells (T 
cells, B cells, monocytes and endothelial cells), leading to the release of anti-inflammatory 
cytokines. (63,64)  
Several studies on animal models of MS argue about the relevance of cholinergic anti-
inflammatory pathway in MS pathogenesis. In mice with autoimmune experimental acute 
encephalomyelitis, deficient on subunit alpha 7 nicotinic acetylcholine receptors, subtle 
changes in the expression of pro-inflammatory and anti-inflammatory cytokines were 
observed with a higher expression of interleukin 10, interleukin 1 factor 9, and inhibin alpha. 
(65) More pronounced changes were observed in another study, which demonstrated that 
subunit alpha 7 nicotinic acetylcholine receptors play an important role in the reduction of 
inflammatory response conferred by nicotine in autoimmune experimental acute 
encephalomyelitis. (66) However, recent data demonstrate that several nicotinic 
acetylcholine receptor subtypes are involved, albeit differently, in the cholinergic anti-
inflammatory pathway, indicating that each nicotinic acetylcholine receptor subtype may 
modulate unique cellular immune functions. (67) Specifically, it has been suggested that 
disease exacerbation (or even induction) is being mediated at least in part via alpha 9 nicotinic 
acetylcholine receptor in peripheral immune cells, but also protective roles of central nervous 
system alpha 7 nicotinic acetylcholine receptor have also been suggested. (68) Discovery of 
acetylcholine producing T cells capable to regulate inflammation has proved importance of 
neural circuit as rheostat mechanism in immunomodulation. (69) 
As nicotine, which acts via nicotinic acetylcholine receptors, is one of the principal 
components of cigarette smoke, it is interesting that substantial body of evidence supports 
the causal involvement of smoking in the development and progression of MS. (70) Studies on 
the effect of nicotine on immune system have been contradictory, some finding pro- and some 
anti-inflammatory effects. (71) Studies on animal models of MS, experimental autoimmune 
encephalomyelitis (EAE), found that nicotine improves EAE symptoms, the clinical scores and 
demyelination status, in contrast to cigarette smoke condensate which cuased a worsening 
course of the disease. (72) Even more interestingly, a therapeutic intervention in EAE 
combining mesenchymal stem cells and nicotine led to a significant reduction in the 
cumulative disease disability better than the treatment with either therapy alone. (73) 
Furthermore, the combination treatment caused a significant decline in the production of the 
pro-inflammatory interleukin-17, tmor necrosis factor-α, and interferon-γ cytokines and 
simultaneously caused a meaningful increase in the production of the anti-inflammatory 
interleukin-10. 
All these data give a molecular background to previously mentioned clinical and 
neurophysiological data supporting the role of ANS dysfunction in MS. However, correlation 
studies taking into account clinical, neurophysiological and molecular aspects are missing and 
would help us in better understanding of immune-ANS interaction disturbances in MS. 
 Conclusion 
 
Results of the studies published so far have shown a distinctive pattern of AD in pwMS. While 
the disease activity, which is more prevalent in pwCIS and early RRMS, is associated with 
sympathetic nervous system dysfunction, parasympathetic nervous system dysfunction 
becomes more evident with the progression of the disease, with highest percentages of 
involvement seen in advanced progressive MS. On a molecular level, changes in expression of 
different receptors responsible for the communication between ANS and immune systems 
may modulate inflammatory response and thus have an influence on MS disease activity or 
progression. Whether these observed ANS changes are drivers of the inflammation and/or 
neurodegeneration, or they are just a consequence of MS lesions in the central nervous 
system remains to be elucidated.  
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Table 1. Studies investigating different types of autonomic dysfunction in patients with multiple sclerosis using different autonomic tests.  
 
Reference Number of 
participants 
MS phenotype Sympathetic 
dysfunction 
Parasympathetic 
dysfunction 
Sudomotor 
dysfunction 
Noronha et al., 1968 (31) 60 NR NR NR 42%a 
Mutani et al., 1982 (32) 10 NR NR 40%b NR 
Senaratne et al., 1984 (33) 11 NR NR 55%b NR 
19 NR 16%d 21%c NR 
Pentland et al., 1987. (34) 50 NR 0%e 8%c, 30%b NR 
Yokota et al., 1991 (35) 28 RRMS NR NR 75%f 
Anema et al., 1991 (36) 34 NR 13%e (out of 30 patients)  36%b NR 
Thomaides et al., 1993 (37) 10 SPMS 0%g 0%b,c NR 
Gutrecht et al., 1993 (38) 29 NR NR NR 59%f 
Vita et al., 1993 (17) 40 NR 0%e 18%b NR 
Elie et al., 1995 (39) 70 RRMS 41, PMS 29 NR NR 94%f 
Linden et al., 1995 (40) 30 NR 14%e (out of 22 patients) 10%b 67%f 
Caminero et al., 1995 (41) 63 NR NR NR 41%f 
Linden et al., 1997 (42) 20 NR 5%g 25%b 75%f 
Nasseri et al., 1999 (22) 20 RRMS NR 20%b NR 
Flachenecker et al., 1999 (12) 40 RRMS, SPMS 8%e 3%c, 10%b NR 
Acevedo et al., 2000 (10) 40 RRMS 30, PMS 10 38%e 43%c, 30%b NR 
de Seze et al., 2001 (11) 25 RRMS 0%e 0%h 30%f 
25 SPMS 20%e 12%h 48%f 
25 PPMS 32%e 12%h 48%f 
Merkelbach et al., 2001 (43) 54 RRMS 22%e 2%c, 22%b NR 
14 SPMS 29%e 7%c, 29%b NR 
16 PPMS 31%e 25%c, 31%b NR 
Gunal et al., 2002 (44) 22 RRMS 9%e 14%c, 18%b 18%f 
McDougall et al., 2003 (45) 63 RRMS 39, SPMS 21 and PPMS 3 3%d, 3%g 0%c, 16%b 45%f 
Labuz-Roszak et al., 2007 (46) 24 RRMS 11, SPMS 10 and PPMS 3 19%e 4%c, 29%b 75%f 
Lorberboym et al., 2008 (47) 10 RRMS 7, SPMS 3 NR 30%c, 50%b NR 
Saari et al., 2008. (48) 27 RRMS 21, SPMS 6 NR NR 52%f 
Hale et al., 2009 (49) 31 RRMS 22, SPMS 5 and PPMS 2 (2 
unknown type) 
26%g 6%c, 10%b NR 
Aghamollaii et al., 2011 (50) 30 CIS 9, RRMS 21 NR NR 77%f 
Adamec et al., 2013 (51) 112 RRMS 11%g NR NR 
Crnošija et al, 2016 (52) 24 CIS 38%d, 8%g 4%c, 0%b 31%i (out of 16 
patients) 
Habek et al., 2016 (14) 104 CIS 34%d, 8%g 1%c, 4%b 33%i 
Adamec et al., 2018 (15) 40 RRMS 36%j 3%k 35%i 
30 PMS 61%j 20%k 73%i 
 
NR not reported; CIS clinically isolated syndrome; RRMS relapsing remitting multiple sclerosis; SPMS secondary progressive multiple sclerosis; 
PPMS primary progressive multiple sclerosis; PMS progressive multiple sclerosis; a thermoregulatory sweat testing; b deep breathing test; c 
Valsalva ratio, d systolic BP response to Valsalva maneuvre, e active standing, f sympathetic skin response, g tilt table, h composite measure of 3 
parasympathetic tests including deep breathing and Valsava ratio, i QSART, j adrenergic index, k cardiovagal in
Figures 
 
Figure 1. Autonomic dysfunction (AD) in people with multiple sclerosis (pwMS) can be 
demonstrated clinically and on molecular level. Clinically it can be demonstrated by measuring 
autonomic symptoms with Composite Autonomic Symptom Score (COMPASS-31) and 
neurophysiologically with different autonomic nervous system tests. Both symptomatic and 
objectively determined AD can be related to increased risk of multiple sclerosis (MS) disease 
activity, and abnormalities on different autonomic nervous system tests may be associated 
with an increased risk of cardiovascular comorbidities. The cause of AD in pwMS is probably 
associated with demyelinating lesions in the brainstem and atrophy of the cervical spinal cord, 
however once present it can cause a vicious circle of new lesions which can again worsen AD. 
Further supporting these clinical observations are molecular changes on immune cells. 
Changes in the sympathetic autonomic system like different expression dopaminergic 
receptor (DR) D3 and α2A-adrenergic receptor (AR) mRNAs in peripheral blood mononuclear 
cells, and dopaminergic receptor D5 mRNA in T regulatory cells may be associated with MS 
disease activity. Similarly, modulation of the cholinergic anti-inflammatory pathway over 
different subunits of the nicotinic acetylcholine receptor (nAChR) in peripheral immune may 
mediate different effects on MS disease activity. 
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